Advertisement

Topics

Braeburn Pharma Release: Phase II Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder

20:00 EDT 22 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Braeburn Pharma Release: Phase II Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder

NEXT ARTICLE

More From BioPortfolio on "Braeburn Pharma Release: Phase II Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder"

Advertisement
Quick Search
Advertisement
Advertisement